Dashboard
Manage Tickers

MRKMerck & Co., Inc.

NYSE merck.com


$ 130.90 $ 0.23 (0.18 %)    

Monday, 10-Jun-2024 09:56:18 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 462.16 $ -0.63 (-0.14 %)
DIA $ 388.63 $ 0.28 (0.07 %)
SPY $ 532.95 $ -0.30 (-0.06 %)
TLT $ 90.96 $ -0.07 (-0.08 %)
GLD $ 213.17 $ 0.08 (0.04 %)
$ 130.67
$ 130.67
$ 0.00 x 0
$ 131.60 x 127
$ 130.61 - $ 131.37
$ 97.81 - $ 133.10
4,945,599
na
330.96B
$ 0.33
$ 143.52
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 02-26-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

nike-merck-general-motors-and-more-cnbcs-final-trades
Nike, Merck, General Motors, And More: CNB...
06/10/2024 12:14:30

Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of ...

market-whales-and-their-recent-bets-on-mrk-options
Market Whales and Their Recent Bets on MRK...
06/07/2024 20:01:20

Core News & Articles
CNBC Halftime Report Final Trades: Nike, M...
06/07/2024 17:00:45

promising-trial-results-show-new-standards-in-cancer-treatment-and-diagnostics-are-on-the-horizon
Promising Trial Results Show New Standards...
06/04/2024 17:45:09

On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a...

cantor-fitzgerald-reiterates-overweight-on-merck--co-maintains-155-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/04/2024 17:26:42

Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.

comparative-study-merck-amp-co-and-industry-competitors-in-pharmaceuticals-industry
Comparative Study: Merck & Co And Indu...
06/04/2024 15:00:39

moderna-merck-reveal-three-year-data-for-individualized-cancer-therapy-in-high-risk-melanoma-patients
Moderna, Merck Reveal Three Year Data For ...
06/03/2024 14:27:16

Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free an...

Core News & Articles
Moderna And Merck Announced The First Pres...
06/03/2024 12:11:18

With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination wit...

summit-therapeutics-lung-cancer-therapy-ivonescimab-shows-improved-progression-free-survival-versus-mercks-multi-billion-keytruda-in-china-study
Summit Therapeutics' Lung Cancer Therapy I...
05/31/2024 14:21:15

Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company ann...

smart-money-is-betting-big-in-mrk-options
Smart Money Is Betting Big In MRK Options
05/30/2024 20:01:23

Core News & Articles
Summit Therapeutics Announces Phase III Tr...
05/30/2024 18:31:23

Unprecedented: Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase II...

merck-says-fda-accepted-for-priority-review-a-new-supplemental-biologics-license-application-seeking-approval-for-keytruda-in-combination-with-chemotherapy
Merck Says FDA Accepted For Priority Revie...
05/29/2024 11:19:58

This is for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. The F...

merck-agrees-to-buy-eyebiotech-for-13b-upfront-payment-and-up-to-17b-in-future-milestone-payments-for-a-potential-value-of-3b
Merck Agrees To Buy Eyebiotech For $1.3B U...
05/29/2024 10:46:54

merck-reportedly-nearing-13b-acquisition-of-eyebio-to-expand-eye-care-market-presence
Merck Reportedly Nearing $1.3B Acquisition...
05/29/2024 08:36:53

Merck & Co is reportedly on the verge of acquiring EyeBio, an eye-drug company, for a sum of $1.3 billion. This acquisition...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/28/2024 17:35:22

mercks-multi-billion-cancer-drug-keytruda-aces-late-stage-breast-cancer-study-updated
Merck's Multi-Billion Cancer Drug Keytruda...
05/28/2024 16:04:40

Merck's KEYNOTE-522 trial shows Keytruda combined with chemotherapy significantly improves overall survival in high-risk ea...

mercks-keytruda-shows-improvement-in-survival-for-early-stage-tnbc-patients
Merck's KEYTRUDA Shows Improvement in Surv...
05/28/2024 10:47:04

KEYTRUDA® (pembrolizumab) is the first and only immunotherapy-based regimen to show a statistically significant improvement in ...

astrazeneca-merck-gsk-struck-record-441b-licensing-deals-with-chinese-drugmakers-in-2023-report
AstraZeneca, Merck, GSK Struck Record $44....
05/27/2024 11:12:58

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.

why-is-cancer-focused-merus-stock-trading-over-30-on-friday
Why Is Cancer-Focused Merus Stock Trading ...
05/24/2024 17:41:19

Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and...

performance-comparison-merck-amp-co-and-competitors-in-pharmaceuticals-industry
Performance Comparison: Merck & Co And...
05/21/2024 15:00:40

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION